Roche Launches AXELIOS 1, a Next-Generation Sequencing Platform Delivering Same-Day Whole-Genome Results

Roche查看公司主页 announced on June 29, 2026, the launch of AXELIOS 1 (搜索)搜索该药品, a next-generation single-molecule sequencing platform powered by the company's proprietary sequencing by expansion (SBX) technology. The platform represents a significant advancement in genomics research, delivering a unique combination of accuracy, speed, flexibility, scalability, and cost efficiency that addresses critical bottlenecks in both genomics and clinical research.

"AXELIOS 1 (搜索)搜索该药品 will deliver a disruptive sequencing solution that combines high accuracy with unprecedented speed and scalability. These attributes, combined with our high level of cost efficiency, will enable the sequencing community to develop applications that previously were not feasible," said Matt Sause, CEO of Roche查看公司主页 Diagnostics. "Additionally, in the future, AXELIOS 1 has the same potential to enable the next generation of clinical applications and unlock new frontiers in personalised healthcare."

The SBX Technology: A Novel Approach to Sequencing

At the core of the AXELIOS 1 (搜索)搜索该药品 platform is the sequencing by expansion (SBX) technology, a novel approach that uses a sophisticated biochemical process to encode the sequence of a target nucleic acid molecule — DNA or RNA — into a measurable surrogate polymer called an "Xpandomer." These Xpandomers are approximately fifty times longer than the original molecule and encode sequence information into high signal-to-noise reporters, providing clear signals with minimal background noise when threaded through a nanopore. This design significantly improves the accuracy of single-molecule sequencing.

The SBX chemistry is coupled with a reusable, high-throughput complementary metal–oxide–semiconductor (CMOS) sensor module containing millions of nanopores, along with an advanced analysis module that enables ultra-rapid, near real-time base calls and analysis. The platform is fundamentally designed for flexibility and performance, capable of handling everything from smaller, faster batches to large-scale genomic projects without requiring changes to systems or workflows.

Proven Real-World Capabilities

AXELIOS 1 (搜索)搜索该药品 launches with demonstrated real-world capabilities through collaborations with leading institutions, including Hartwig Medical Foundation (搜索)搜索该词条 and Broad Clinical Labs (搜索)搜索该词条. Studies conducted with these partners have confirmed that the platform delivers impressive accuracy and throughput with record-breaking speed and superior cost efficiency. Early-access users have also garnered the world record for the fastest DNA sequencing technique.

The collaborative ecosystem extends to library preparation and analysis tools. Roche查看公司主页 has established a partnership with 10x Genomics (搜索)搜索该公司 for single-cell and spatial application kits, and the platform supports SBX via Google DeepVariant as well as the open-source suite of XOOS tools. Roche will also offer its own library prep kits and a free open-source bioinformatics analysis suite tailored for SBX technology.

Since the SBX technology was unveiled in early 2025, multiple research applications have been tested as proof of principle, including whole-genome sequencing, RNA-sequencing, single-cell RNA, spatial, and methylation analyses. Early-access users have demonstrated practical research applications across oncology, genetics, and infectious diseases.

Market Context and Future Potential

The global sequencing market is valued at approximately $7.3 billion, with overall growth projected to reach double digits within the next few years across both research and clinical sectors. Since sharing early access data, Roche查看公司主页 reports strong interest in the SBX technology from the sequencing community.

The platform's flexible sequencing run setup and high throughput enable laboratories of all sizes to expand their research capabilities with a single instrument. Workflows can be adapted for various experimental needs, including reads of up to approximately 1,500 base pairs under appropriate sample and library preparation conditions, and ultra-fast processing from sample to Variant Calling Format.

AXELIOS 1 (搜索)搜索该药品 is currently designated for research use only and is not for use in diagnostic procedures. However, Roche查看公司主页 has indicated that the platform holds promise for a broad range of clinical settings in the future, with the potential to replace existing technologies in pivotal research areas and enable the next generation of clinical applications in personalised healthcare.